Amgen (AMGN) World Lung KRAS Update Supports Rapid Filing Strategy - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Baird Reiterates Neutral Rating on Amgen (AMGN)
September 9, 2019 8:26 AM EDTBaird analyst Brian Skorney reiterated a Neutral rating and $173.00 price target on Amgen (NASDAQ: AMGN)
The analyst comments "Amgen's updated KRAS lung cancer data continue to look good, although compared to the super-high expectations set by the ASCO data, there is likely... More
